Academic Press Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2: Diagnosis, Therapeutic Targets, and Molecular Mechanisms

Product Description Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies. This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting. Review Presents an up-to-date overview of all aspects of the diagnosis, therapeutic targets and therapies for hepatocellular carcinoma From the Back Cover <p><i>Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma</i> provides comprehensive information about on-going research as well as clinical data about liver cancer. It presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes.</p> <p>The second volume, <i>Diagnosis, Therapeutic Targets and Therapy</i>, discusses topics such as computational approaches for identification of biomarkers, enzymes, and pathways of HCC; circulating and epigenetic biomarkers; drug resistance; metabolic pathways; and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors, and nanotechnology-based therapies.</p> <p>It is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists, and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.</p> About the Author Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 70 research papers in highly reputed International journals and has presented more than 50 abstracts at various national and international conferences. Dr, Nagaraju is author and editor of several published books including 1. Role of Tyrosine Kinases in Gastrointestinal Malignancies, 2. Role of Transcription Factors in Gastrointestinal Malignancies and 3. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR). Dr Vadde Ramakrishna is Assistant Professor at the Department of Biotechnology & Bioinformatics, Yogi Vemana University, India. He obtained his MSc and PhD, b